Logo

MBRX

Moleculin Biotech, Inc.

MBRX

Moleculin Biotech, Inc. • NASDAQ
$0.27 ▼ -2.61% (-0.01)
Market Cap $8.24 M
52w High $91.25
52w Low $0.27
Dividend Yield 0%
P/E -0.01
Volume 1.69M
Outstanding Shares 30.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.885M ▲ $-25.399M ▼ 0% $-0.68 ▼ $-25.378M ▼
Q2-2025 $0 $5.691M ▼ $-7.64M ▼ 0% $-0.49 ▲ $-7.611M ▼
Q1-2025 $0 $5.943M ▼ $-6.436M ▼ 0% $-68.88 ▼ $-5.912M ▼
Q4-2024 $0 $6.612M ▼ $-1.882M ▲ 0% $-0.56 ▲ $-1.851M ▲
Q3-2024 $0 $7.135M $-10.592M 0% $-2.85 $-7.103M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.703M ▼ $20.353M ▼ $47.273M ▲ $-26.92M ▼
Q2-2025 $7.557M ▼ $21.593M ▲ $28.758M ▲ $-7.165M ▼
Q1-2025 $7.716M ▲ $21.013M ▲ $20.971M ▲ $42K ▼
Q4-2024 $4.278M ▼ $16.925M ▼ $10.946M ▼ $5.979M ▼
Q3-2024 $9.405M $23.394M $15.915M $7.479M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-25.399M ▼ $-7.223M ▼ $0 $6.375M ▲ $-854K ▼ $-7.223M ▼
Q2-2025 $-7.64M ▼ $-5.582M ▼ $0 $5.423M ▼ $-159K ▼ $-5.582M ▼
Q1-2025 $-6.436M ▼ $-4.564M ▲ $0 $7.999M ▲ $3.438M ▲ $-4.564M ▲
Q4-2024 $-1.882M ▲ $-5.083M ▲ $0 $1K ▼ $-5.127M ▼ $-5.083M ▲
Q3-2024 $-10.592M $-6.113M $0 $4.659M $-1.44M $-6.113M

Five-Year Company Overview

Income Statement

Income Statement Moleculin is still a pure research-stage biotech. It has reported essentially no product revenue for several years, so the income statement is driven entirely by R&D and overhead costs. Losses have been steady year after year, reflecting ongoing clinical development rather than any commercial activity. Per‑share losses look large mainly because the share count has been adjusted multiple times through reverse splits, not because of a dramatic jump in underlying spending. Overall, this is a classic early‑stage biotech profile: no sales yet, recurring operating losses, and economic success hinging on future trial outcomes and potential approvals rather than current earnings power.

Balance Sheet

Balance Sheet The balance sheet is small and relatively simple. Assets are dominated by cash and equivalents, and those cash levels have come down over time, signaling that past financings are being drawn down to fund trials. There is effectively no financial debt, which reduces balance‑sheet risk but also means the company depends heavily on raising new equity or partnering to keep funding operations. Book equity has declined as cumulative losses build, leaving a thin capital base and underscoring sensitivity to financing conditions and trial results.

Cash Flow

Cash Flow Cash flows are negative and driven almost entirely by operating activities, particularly R&D spending and general corporate costs. There is little to no capital expenditure, so the cash burn is mostly about paying for clinical trials, staff, and overhead rather than physical assets. The size of the cash outflow has been fairly consistent, which makes the burn profile somewhat predictable but also highlights ongoing dependence on external funding. Without incoming revenue or large upfront partnership payments, the company will likely need periodic capital raises to sustain its trial programs.

Competitive Edge

Competitive Edge Competitively, Moleculin is a small player in a very crowded oncology field, but it is targeting difficult cancers where existing treatments are poor and competition is thinner. Its edge is based on specialized science rather than commercial scale: a next‑generation chemotherapy designed to avoid heart damage and drug resistance, a STAT3 inhibitor that also stimulates the immune system, and a metabolism‑targeting drug that can reach the brain. Strong patent coverage and orphan‑drug designations help protect these programs if they succeed. However, as a small, pre‑revenue company, Moleculin lacks the marketing, manufacturing, and global trial infrastructure of larger pharma, making eventual partnerships or collaborations important to its competitive posture.

Innovation and R&D

Innovation and R&D Innovation is the core of Moleculin’s story. The lead asset, Annamycin, aims to improve on a well‑known class of chemotherapy by reducing heart toxicity and overcoming common resistance mechanisms, with a pivotal trial underway in hard‑to‑treat leukemia. Two additional programs, WP1066 and WP1122, are focused on brain and other aggressive tumors through immune modulation and cancer metabolism, including the ability to cross the blood–brain barrier. The R&D strategy is high‑risk but focused: multiple shots on goal within oncology, all targeting areas of clear unmet need. Timelines are long, and key value drivers are future trial readouts and regulatory decisions, so investors face significant uncertainty but also meaningful potential upside if the science translates into strong clinical data.

Summary

Moleculin Biotech is a classic clinical‑stage oncology company: no product revenue yet, steady operating losses, and a small, cash‑heavy but shrinking balance sheet with no debt. Its financial sustainability depends on its ability to keep raising capital or securing partners while advancing its pipeline. On the strategic side, the company is tightly focused on innovative cancer drugs that aim to fix known weaknesses in current treatments, supported by a growing patent estate and orphan‑drug status in certain indications. The upside case rests on successful late‑ and mid‑stage trials, especially for Annamycin, while the downside revolves around trial setbacks, delays, or funding constraints. Overall, this is a high‑risk, high‑uncertainty biotech profile where long‑term outcomes are driven far more by scientific and regulatory milestones than by current financial metrics.

NEWS

November 26, 2025 · 9:15 AM UTC

Moleculin to Participate in the Virtual Investor Closing Bell Series

Read more

November 26, 2025 · 9:00 AM UTC

Moleculin Announces Reverse Stock Split

Read more

November 13, 2025 · 8:36 AM UTC

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Read more

November 12, 2025 · 8:37 AM UTC

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Read more

October 30, 2025 · 8:40 AM UTC

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Read more